Johnson & Johnson (JNJ) just announced the acquisition of privately-held Aragon Pharmaceuticals and the rights to ARN-509 a
- ASCO GU 2014: Why does the Medivation PREVAIL trial matter?
- Dr Oliver Sartor shares his thoughts on Prostate Cancer data at ECCO 2013
- ECCO 2013: Is ODM-201 too late to the prostate cancer party?
- Orteronel (TAK-700) fails in Advanced Prostate Cancer
- ASCO GU 2013 Prostate Cancer Preview #GU13
- Court rules Medivation has no IP rights to Aragon Pharmaceuticals ARN-509 $MDVN
- ESMO 2012 ODM-201 shows promise as a future competitor to enzalutamide
- ESMO 2012: ODM-201 a new generation antiandrogen for advanced prostate cancer
- ASCO 2012: Zytiga fails to show overall survival pre-chemo